Treatments for age-related macular degeneration (AMD)
AssigneeThe Regents of the University of California
InventorsDaniel M. Schwartz, Keith G. Duncan, Kathy R. Bailey, John P. Kane, Brian Y. Ishida
Life of this patent
Estimating the term…
Abstract
The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.
Claims25
A method of treating macular degeneration in an individual, comprising the step of increasing reverse cholesterol transport in an ocular tissue of the individual.
A method of preventing and/or reducing lipid accumulation in an ocular tissue, comprising the step of increasing the level of a lipid transporter in said tissue.
A method of increasing lipid efflux from an ocular tissue comprising the step of increasing the level of at least one lipid transporter in said tissue.
A method of treating macular degeneration (AMD) in an individual, comprising the step of delivering a therapeutically effective amount of at least one lipid transporter to at least one tissue of the individual.
A kit for the prevention or treatment of macular degeneration, housed in a suitable container, comprising a lipid transporter.
Dependencies are inferred from the claim text.